Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.

Karen L SmithFengmin ZhaoIngrid A MayerAmye J Tevaarwerk Sofia F GarciaCarlos L ArteagaWilliam F SymmansBen H ParkBrian L BurnetteDella F MakowerMargaret BlockKimberly A MorleyChirag R JaniCraig MescherShabana J DewaniUrsa Brown-GlabermanLisa E FlaumErica L MayerWilliam M SikovEve T RodlerAngela M DeMicheleJoseph A SparanoAntonio C WolffKathy D MillerLynne I Wagner

Published in: Cancer (2024)

Despite the similar frequency of clinician-rated AEs, PROs identified greater on-treatment symptom burden with capecitabine and complemented clinician-rated AEs by characterizing patients' experiences during chemotherapy.

Keyphrases

patient reported outcomes
locally advanced
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
early stage
phase ii study
mental health
squamous cell carcinoma
randomized controlled trial
clinical trial
metastatic colorectal cancer
patient reported
radiation therapy
open label